Aberrant accumulation of β-
catenin plays an important role in a variety of human
neoplasms. This can be caused by stabilizing mutation of β-
catenin (CTNNB1, exon 3) or by mutation or deregulated expression of other components of the WNT/β-
catenin signaling pathway. Accumulation of non-phosphorylated active β-
catenin has been reported to commonly occur in
parathyroid adenomas from patients with
primary hyperparathyroidism (pHPT), either due to the aberrantly spliced internally truncated WNT receptor LRP5 (LRP5Δ) or to a stabilizing mutation of β-
catenin. The S37A mutation was reported to occur in 7.3 % in a single study of
parathyroid adenomas, while in other studies no stabilizing mutations of β-
catenin exon 3 were identified. The aim of this study was to determine the mutational frequency of the CTNNB1 gene, specifically exon 3 in a large series of
parathyroid adenomas. One hundred and eighty sporadic
parathyroid adenomas were examined for mutations in exon 3 of CTNNB1 by direct
DNA sequencing, utilizing previously published primer sequences. The mutation S33C (TCT>TGT) was detected by direct-
DNA sequencing of PCR fragments in 1 out of 180 sporadic
parathyroid adenomas (0.68 %). Like
serine 37, mutations of
serine 33 have been reported in many
neoplasms with resulting β-
catenin stabilization, enhanced transcription, and oncogenic activities. Immunohistochemical analysis revealed an overexpression of the β-
catenin protein in the lone mutant
tumor. Taking also previous studies into account we conclude that activating mutations of the regulatory GSK-3β phosphorylation sites
serine 33 and 37, encoded by CTNNB1 exon 3, rarely occur in
parathyroid adenomas from patients with pHPT.